Top

Administration and Policy in Mental Health and Mental Health Services Research

Published in:

01-03-2007 | Original paper

Treatment with Antidepressant Medications in Private Health Plans

Authors: Mary Jo Larson, Kay Miller, Kathleen J. Fleming

Published in: Administration and Policy in Mental Health and Mental Health Services Research | Issue 2/2007

Abstract

This study analyzed 2002 MarketScan data from a convenience sample of enrollees with private health insurance from the largest U.S. firms to examine utilization, expenditures, and factors associated with antidepressant prescriptions. Of enrollees, 11% received at least one antidepressant prescription during the year with average expenditures per enrollee of $51.55. Antidepressant prescriptions were more frequently used than any form of other mental health care and for 42% of users was not associated with any clearly identified mental health or “off-label” indication. In logistical regression analyses, health plan type, prescription days supply, gender, region, age, employment status, and subscriber status were associated with unexplained antidepressant prescription use.

Available only for authorised users

For Zoloft and Prozac ‘Premenstrual Dysphoric Disorder’ is a labeled condition.

Adams, C., & Young, A. (2003, November 2–4). Off-label prescribing, an investigative series by Knight-Ridder. Knight-Ridder Newspapers.

Asarnow, J. R., Jaycox, L. H., Duan, N., LaBorde, A. P., Rea, M. M., Murray, P., et al. (2005). Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: A randomized controlled trial. Journal of the American Medical Association, 293(3), 311–319.PubMedCrossRef

Barents Group LLC (1999). Factors affecting the growth of prescription drug expenditures. Washington, DC: The National Institute for Health Care Management Research and Educational Foundation.

Coffey, R. M., Mark, T., King, E., Harwood, H., McKusick, D., Genuardi, J., et al. (2000, July). National estimates of expenditures for mental health and substance abuse treatment, 1997 (No. SAMHSA Publication No. SMA-00–3499). Rockville, MD: Center for Substance Abuse Treatment and Center for Mental Health Services, Substance Abuse and Mental Health Services Administration.

Cooper, W. O., Arbogast, P. G., Ding, H., Hickson, G. B., Fuchs, D. C., & Ray, W. A. (2006). Trends in prescribing of antipsychotic medications for US children. Ambulatory Pediatrics, 6(2), 79–83.PubMedCrossRef

Coyle, J. T. (2000). Psychotropic drug use in very young children. Journal of the American Medical Association, 283(8), 1059–1060.PubMedCrossRef

Croghan, T. W., & Pittman, P. M. (2004). The medicine cabinet: What’s in it, why, and can we change the contents? Health Affairs (Millwood), 23(1), 23–33.CrossRef

Croghan, T. W. (2001) The controversy of increased spending for antidepressants. Health Affairs (Millwood), 20, 129–135.CrossRef

FDA (2004). Antidepressant use in children, adolescents, and adults. Retrieved October 12, 2004, from http://www.fda.gov/cder/drug/antidepressants/default.htm

FDA (2005). Summaries of medical and clinical pharmacology reviews—pediatric studies. Retrieved June 10, 2005, from http://www.fda.gov/cder/pediatric/Summaryreview.htm

Guck, T. P., Kavan, M. G., Elsasser, G. N., & Barone, E. J. (2001). Assessment and treatment of depression following myocardial infarction. American Family Physician, 64(4), 641–648.PubMed

Katon, W., Von Korff, M., Lin, E., Simon, G., Walker, E., Bush, T., et al. (1997). Collaborative management to achieve depression treatment guidelines. Journal of Clinical Psychiatry, 58(Suppl 1), 20–23.PubMed

Katon, W. J., Roy-Byrne, P., Russo, J., & Cowley, D. (2002). Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Archives of General Psychiatry, 59(12), 1098–1104.PubMedCrossRef

Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., et al. (2003). The epidemiology of major depressive disorder: Results from the national comorbidity survey replication (NCS-R). Journal of the American Medical Association, 289(23), 3095–3105.PubMedCrossRef

Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 62(6), 617–627.PubMedCrossRef

Larson, M. J., Miller, K., & Fleming, K. J. (2004). Mental health services and psychotropic drug use in employer-sponsored health plans, 2002. Final report submitted to Center on Mental Health Services (Judith Teich, project officer), December, 2004.

Larson, M. J., Miller, K. & Fleming, K. J. (2006). Datapoints: Antidepressant medication use in private insurance health plans, 2002. Psychiatric Services, 57, 175.PubMedCrossRef

Le Melledo, J. M., Bailey, D., & Baker, G. B. (2004). Selective serotonin reuptake inhibitors and myocardial infarction. Circulation, 109(3), E19.CrossRef

Loder, E. W., & Biondi, D. M. (2004). Off-label prescribing of drugs in specialty headache practice. Headache, 44(7), 636–641.PubMedCrossRef

Manisses Communications Group (2003). The psychopharmacology desktop reference (3rd ed.). Providence, RI: Manisses Communications Group, Inc.

Mark, T. L., Coffey, R. M., Vandivort-Warren, R., Harwood, H. J., King, E. C., & MHSA Spending Estimates Team, A. T. (2005, March 29). U. S. Spending for mental health and substance abuse treatment, 1991–2001. Health Affairs (Millwood). Retrieved April 5, 2005, from http://www.content.healthaffairs.org/cgi/content/abstract/hlthaff.w5.133.

McCorry, F., Garnick, D. W., Bartlett, J., Cotter, F., & Chalk, M. (2000). Developing performance measures for alcohol and other drug services in managed care plans. The Joint Commission Journal of Quality Improvement, 26(11), 633–643.

National Institute of Mental Health (2003). Childhood-onset schizophrenia: An update from the National Institute of Mental Health. Bethesda (MD): NIMH, National Institutes of Health, US Department of Health and Human Services. (NIH Publication Number: NIH 5124). Accessed, April 1, 2006, http://www.nimh.nih.gov/publicat/schizkids.cfm

National Committee for Quality Assurance (2005). The State of Health Care Quality 2005. NCQA: Washington DC. Accessed April 1, 2006. http://www.ncqa.org/Docs/SOHCQ_2005.pdf

Olfson, M., Gameroff, M. J., Marcus, S. C., & Waslick, B. D. (2003). Outpatient treatment of child and adolescent depression in the united states. Archives of General Psychiatry, 60(12), 1236–1242.PubMedCrossRef

Olfson, M., Marcus, S. C., Druss, B., Elinson, L., Tanielian, T., & Pincus, H. A. (2002). National trends in the outpatient treatment of depression. Journal of the American Medical Association, 287(2), 203–209.PubMedCrossRef

Olfson, M., Marcus, S. C., Pincus, H. A., Zito, J. M., Thompson, J. W., & Zarin, D. A. (1998). Antidepressant prescribing practices of outpatient psychiatrists. Archives of General Psychiatry, 55(4), 310–316.PubMedCrossRef

Ornstein, S., Stuart, G., & Jenkins, R. (2000). Depression diagnoses and antidepressant use in primary care practices: A study from the Practice Partner Research Network (PPRNet). Journal of Family Practice, 49(1), 68–72.PubMed

PDR (2002). Physician’s desk reference—Drug guide for mental health professionals-first edition (1st ed.). Montvale, NJ: Thomson Medical Economics.

Pomerantz, J. M. (2003). Antidepressants used as placebos: Is that good practice? Drug Benefit Trends, 15(8), 32–33.

Pomerantz, J. M., Finkelstein, S. N., Berndt, E. R., Poret, A. W., Walker, L. E., Alber, R. C., et al. (2004). Prescriber intent, off-label usage, and early discontinuation of antidepressants: A retrospective physician survey and data analysis. Journal of Clinical Psychiatry, 65(3), 395–404.PubMedCrossRef

Renaud, J., Axelson, D., & Birmaher, B. (1999). A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents. Drug Safety, 20(1), 59–75.PubMedCrossRef

Robinson, R. L., Long, S. R., Cheng, S., Able, S., Baser, O., Obenchain, R. L., et al. (2006). Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: Analysis of administrative claims. Journal of Managed Care Pharmacy, 12(1), 43–54.PubMed

Ross, E. C. (1997). Managed behavioral health care premises, accountable systems of care, and AMBHA’s PERMS. Evaluation Review, 21(3), 318–321.PubMedCrossRef

Rost, K., Smith, R., Matthews, D. B., & Guise, B. (1994). The deliberate misdiagnosis of major depression in primary care. Archives of Family Medicine, 3(4), 333–337.PubMedCrossRef

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., et al. (2006). Bupropion-SR, Sertaline, or Venlafaxine-XR after failure of SSRIs for depression. The New England Journal of Medicine, 354, 1231–1242.PubMedCrossRef

Sauer, W. H., Berlin, J. A., & Kimmel, S. E. (2001). Selective serotonin reuptake inhibitors and myocardial infarction. Circulation, 104(16), 1894–1898.PubMedCrossRef

Schulberg, H. C., Katon, W., Simon, G. E., & Rush, A. J. (1998). Treating major depression in primary care practice: An update of the agency for health care policy and research practice guidelines. Archives of General Psychiatry, 55(12), 1121–1127.PubMedCrossRef

Scott, J., Palmer, S., Paykel, E., Teasdale, J., & Hayhurst, H. (2003). Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study. British Journal of Psychiatry, 182, 221–227.PubMedCrossRef

Sekula, L. K., DeSantis, J., & Gianetti, V. (2003). Considerations in the management of the patient with comorbid depression and anxiety. Journal of the American Academy of Nurse Practitioners, 15(1), 23–33.PubMedCrossRef

Simon, G. E., Savarino, J., Operskalski, B., & Wang, P. S. (2006). Suicide risk during antidepressant treatment. American Journal of Psychiatry, 163(1), 41–47.PubMedCrossRef

Stafford, R. S., Ausiello, J. C., Misra, B., & Saglam, D. (2000). National patterns of depression treatment in primary care. Primary Care Companion to the Journal of Clinical Psychiatry, 2(6), 211–216.PubMed

Stone, K. J., Viera, A. J., & Parman, C. L. (2003). Off-label applications for SSRIs. American Family Physician, 68(3), 498–504.PubMed

Tabarrok, A. T. (2000). Assessing the FDA via the anomaly of off-label drug prescribing. The Independent Review, 5(1), 25–53.

Tata, L. J., West, J., Smith, C., Farrington, P., Card, T., Smeeth, L., et al. (2005). General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart, 91(4), 465–471.PubMedCrossRef

Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., et al. (2006). Medication augmentation after the failure of SSRIs for depression. The New England Journal of Medicine, 354, 1243–1252.PubMedCrossRef

U. S. Department of Health and Human Services (1999). Mental health: A report of the surgeon general. Rockville, MD: U. S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health.

Vitiello, B., & Swedo, S. (2004). Antidepressant medications in children. New England Journal of Medicine, 350(15), 1489–1491.PubMedCrossRef

Zuvekas, S. H. (2005). Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Affairs (Millwood), 24(1), 195–205.CrossRef

Title: Treatment with Antidepressant Medications in Private Health Plans
Authors: Mary Jo Larson
Kay Miller
Kathleen J. Fleming
Publication date: 01-03-2007
Publisher: Springer US
Published in: Administration and Policy in Mental Health and Mental Health Services Research / Issue 2/2007
Print ISSN: 0894-587X
Electronic ISSN: 1573-3289
DOI: https://doi.org/10.1007/s10488-006-0088-5

At a glance: The STEP trials

Springer Medicine

Treatment with Antidepressant Medications in Private Health Plans

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

Process and Outcome Evaluation of an Emergency Department Intervention for Persons with Mental Health Concerns Using a Population Health Approach

Leslie Alexander and Phyllis Solomon (eds): The Research Process in the Human Services: Behind the Scenes

Doing the Difficult and Dangerous: The Community Program Practice Scale

Housing Choice and Control, Housing Quality, and Control over Professional Support as Contributors to the Subjective Quality of Life and Community Adaptation of People with Severe Mental Illness

Help-seeking Behaviors of Chinese Patients with Schizophrenia Admitted to a Psychiatric Hospital

Implementing a Depression Improvement Intervention in Five Health Care Organizations: Experience from the RESPECT-Depression Trial